11:04 AM EDT, 05/20/2024 (MT Newswires) -- Arrowhead Pharmaceuticals ( ARWR ) said Monday that a study of its investigational RNAi-based medicine for inflammatory lung disease treatment showed lower serum soluble receptors for advanced glycation end-products, or sRAGE, in asthma patients.

Interim data from the ongoing phase 1/2 study showed that serum sRAGE was cut by up to 88% after two doses of its investigational drug ARO-RAGE in patients with mild to moderate asthma, the company said.

The company added that to date, ARO-RAGE has demonstrated a "favorable safety profile."

The company is expecting to start phase 2 of the study in late 2024, said James Hamilton, Arrowhead Pharmaceuticals' ( ARWR ) chief of discovery and translational medicine.

Price: 24.61, Change: -0.16, Percent Change: -0.65